EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 48 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks... January 27, 2020 What to Say to Someone With Cancer: A Patient Perspective July 14, 2022 Picking out the patterns: How scientists are finding cancer’s signatures in... June 15, 2022 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 Load more HOT NEWS Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in...
